SCHEMBL4350061

SCHEMBL4350061

O=C(NCc1ccccc1)Nc1cc(Cl)c(O)c(Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 1/20 0.55
RAB9A P51151 4/20 0.54
NPC1 O15118 3/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
POLB P06746 1/20 0.54
MAOB P27338 1/20 0.54
HTT P42858 1/20 0.54
TP53 P04637 1/20 0.54
HPGD P15428 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
MAPT P10636 1/20 0.54
KDR P35968 1/20 0.53
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
ROCK2 O75116 1/20 0.52
ROCK1 Q13464 1/20 0.52
GSK3B P49841 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20804368 0.85 NPC1 (0.65) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL4351119 0.85 CA2 (0.60) MTORRAB9ANPC1MAPTKDR
SCHEMBL4351106 0.85 CNR1 (0.68) RAB9ANPC1MEN1KMT2AHTT
SCHEMBL6568451 0.83 KDM4E (0.69) RAB9ANPC1MEN1KMT2AHTT
SCHEMBL4353993 0.82 MTOR (0.67) MTORRAB9APOLBMAPTCA1
SCHEMBL4349130 0.82 RAB9A (0.61) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL4347380 0.82 CA1 (0.56) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL4355796 0.82 MAPT (0.66) RAB9ANPC1MEN1KMT2APOLB
SCHEMBL20911009 0.81 NPC1 (0.67) MTORRAB9ANPC1MEN1KMT2A
SCHEMBL4353325 0.81 CA12 (0.55) MEN1KMT2APOLBHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 MTOR 1379/4885RAB9A 4228/4885NPC1 815/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 MTOR 1296/4885RAB9A 4588/4885NPC1 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.